Abbott to sell Cholestech's GDX system globally:
This article was originally published in Clinica
Abbott is to distribute globally Cholestech's GDX system for the determination of glycated haemoglobin, an indicator of long-term glycaemic control. Abbott will also offer the Cholestech LDX system with the two products representing "a full complement of products for immediate risk assessment and therapeutic monitoring of heart disease and diabetes", according the Timothy Still, Hayward, California-based Cholestech's vice-president of sales and marketing.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.